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Beyond Red Hair and Sunburns:
Uncovering the Molecular
Mechanisms of MC1R Signaling and
Repair of UV-Induced DNA Damage
Pamela B. Cassidy1, Zalfa A. Abdel-Malek2 and Sancy A. Leachman1
Scientists at the University of Kentucky are unraveling the details of DNA-
damage repair in the melanocyte, with an eye towards ﬁnding druggable targets
for melanoma prevention. Jarret et al., (2015, this issue) report in this issue three
new assays that can yield mechanistic information about nucleotide excision
repair (NER) stimulated by cAMP-dependent signaling downstream of the
melanocortin-1 receptor (MC1R).
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Molecularly-targeted prevention
Protecting the lives of individuals and
increasing the productivity of society by
stopping disease before it causes harm
is of the greatest aspirations of
medicine; and as the molecular etiolo-
gies of cancer are discovered, there will
be opportunities to apply targeted
molecular strategies to its prevention,
much as they have been applied to
therapeutics. Consider the development
of targeted therapy for melanoma using
BRAF inhibitors (Puzanov and Flaherty,
2010). This accomplishment resulted
directly from the elucidation of the
molecular mechanism of melanocyte
transformation (V600E mutation of
BRAF) and subsequent identiﬁcation
of a drug that could speciﬁcally
antagonize the mutated protein. To
develop targeted prevention agents, it
will be necessary to elucidate targetable
molecular pathways that predispose a
cell to transformation and then to
identify drugs that can successfully
and safely target these pathways.
Melanoma is a good candidate disease
for the development of targeted
prevention agents because several
melanoma predisposition genes have
been identiﬁed. One of the most
common and well characterized of
these is MC1R (Abdel-Malek et al.,
2014), the target of investigation in an
article from this issue by Jarrett et al.,
(2015).
MC1R and DNA-damage repair
Epidemiological studies have found a
strong correlation between the carriage
of loss-of-function mutations in MC1R
(which encodes a 7-pass transmem-
brane G-protein-coupled receptor) and
both the red-hair phenotype and mela-
noma risk (Pasquali et al., 2015). In cell
culture, treatment of melanocytes that
express the wild-type MC1R (Figure 1),
with the agonist alpha–melanocyte-sti-
mulating hormone (α-MSH), elicits a
variety of responses, including synthesis
of eumelanin, reduction of UV-induced
oxidative stress, stimulation of adenylyl
cyclase and cAMP-dependent signaling,
and enhancement of DNA repair
via base-excision repair and NER
mechanisms (Abdel-Malek et al.,
2014). NER repairs UV-photoproducts
such as cyclobutane pyrimidine
dimers and 6′-4′-pyrimdine-pyrimidone
photoproducts. If not repaired properly,
cyclobutane pyrimidine dimer forma-
tion can result in C4T transitions,
which are a signature mutation in
melanomas (discussed in (Jarrett et al.,
2014)). Thus, impaired NER in the skin
cells of individuals with loss-of-function
MC1R mutations likely contributes to
their vulnerability to melanoma, and it
is therefore a rational target for preven-
tion. Until recently, the mechanistic
details (i.e., demonstrable, quantiﬁable
and targetable molecular events) linking
MC1R activation to NER have been
hazy. Then, it was reported last year
that pre-treatment of melanocytes with
α-MSH augmented their DNA-damage
response by increasing phosphorylation
of DNA-damage sensing proteins ataxia
telangiectasia and Rad3-related protein
(ATR, at serine 428) and ataxia telan-
giectasia mutated (at serine 1981) and
enhancing formation of phosphorylated
γH2AX at nuclear sites of DNA repair
(Swope et al., 2014). And now, in
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this issue, comes the report of an MC1R-
dependent cascade of molecular events
involving phosphorylation of ATR at a
second serine, which directs the recruit-
ment of the key NER protein xeroderma
pigmentosum complementation group
A (XPA) to sites of DNA damage (Jarrett
et al., 2015).
How cAMP and PKA affect recruitment
of critical DNA-damage machinery to
sites of photodamage
The group headed by John D’Orazio at
the University of Kentucky have con-
tributed to our understanding of how
MC1R affects NER in two reports
((Jarrett et al., 2014) and this issue).
The 2014 publication demonstrates
that MC1R-mediated activation of
cAMP-dependent PKA leads to
phosphorylation of ATR at a previously
unrecognized phosphorylation site on
serine 435 (S435, Figure 1). They
show that phosphorylation of ATR
S435 results in an ATR-mediated
recruitment of the NER protein XPA
to sites of nuclear photodamage.
In this way XPA accelerates the
clearance of UV photolesions, includ-
ing cyclobutane pyrimidine dimers and
6′-4′-pyrimdine-pyrimidone photopro-
ducts, and reduces the frequency of
UV-induced mutations. Finally, they
demonstrate clinical relevance by
showing that all of these MC1R-
mediated activities are diminished in
cells bearing loss-of-function mutations
in MC1R and that the activities can be
restored by treatment of melanocytes
with forskolin, a small-molecule activa-
tor of adenylyl cyclase that can bypass
the MC1R deﬁciency (Figure 1). Thus,
the authors have elucidated a detailed
mechanism by which MC1R is able to
reduce UV-induced DNA damage and
the resulting mutations, and they have
identiﬁed a pathway that should be
targeted for melanoma prevention in
individuals who have are deﬁcient in
this repair capacity due to mutations
in MC1R.
New assays will aid in the identiﬁcation
and development of new melanoma
prevention agents
In their paper published here Jarrett
et al., (2015), describe three new assays
that they use to deﬁne the kinetics and
dose-response correlations for MC1R-
mediated ATR phosphorylation and
DNA-damage repair. These assays
enable the authors to carry out detailed
evaluations of the activities of MC1R
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Figure 1. Melanocortin-1 receptor (MC1R) signaling controls repair of UV-induced DNA damage and suppression of mutations via elevation of intracellular
levels of cyclic adenosine monophosphate. MC1R is a G-protein-coupled 7-pass transmembrane receptor expressed on the cell surface of melanocytes. On
binding the agonist α-MSH, conformational changes in MC1R elicit the activation of the heterotrimeric G-protein Gs by exchange of bound GDP for GTP. The
α-subunit of the G-protein (bound to GTP) can then activate adenylyl cyclase, which in turn catalyzes the cyclization of ATP to give cAMP. ASIP and HBD3
interfere with the binding of α-MSH to MC1R (top left). There is also some baseline activity of unstimulated MC1R, which is negatively affected by inverse-agonist
activity of ASIP (top right). cAMP interacts with the inactive heterotetrameric form of PKA, freeing the catalytically active monomer to catalyze the
phosphorylation of ATR on serine 435 giving ATR(pSer435). The physical interaction between ATR(pSer435) and XPA drives the recruitment of XPA to sites of
nuclear photodamage, thereby facilitating repair of the DNA and decreased rates of mutation. ASIP, agouti signaling protein; GDP, guanosine diphosphate; GTP,
guanosine triphosphate; HBD3, human beta-defensin 3; XPA, xeroderma pigmentosum complementation group A; α-MSH, alpha-melanocyte-stimulating
hormone.
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agonists α-MSH and ACTH and MC1R
antagonists agouti signaling protein
(ASIP) and human beta-defensin 3
(HBD3). The ﬁrst assay is a high-
throughput, ﬂuorescence-based assay
that quantiﬁes phosphorylation of
biotinylated 14-mer peptides that corre-
spond to the PKA recognition sequence
containing S435 on ATR. Using this
assay they characterize the kinetics of
ATR S435 phosphorylation by the
recombinant catalytic subunit of PKA.
Then they use nuclear lysates from
melanocytes to determine the effects of
MC1R antagonists ASIP and HBD3 on
the EC50s of α-MSH and forskolin. They
ﬁnd that both antagonists increase the
EC50 of α-MSH but that they have no
effect on the potency of forskolin,
consistent with the schemes illustrated
in Figure 1.
The second assay is adapted by the
authors from the oligonucleotide
retrieval assay, originally published by
Shen et al., (2014). Oligonucleotide
retrieval assay can be used to quantify
the capacity of cells or cell lysates to
repair UV-photodamaged DNA. Repair
is detected by PCR-based ampliﬁcation
of biotinylated oligos, which cannot
take place unless the damaged bases
are removed. Jarrett et al., (2015) use
the assay to show that in human
melanocyte lysates, α-MSH pre-
treatment enhances the repair of photo-
damaged oligos, while concomitant
treatment with ASIP or HBD3 and
α-MSH abolishes this effect. They also
show that ASIP decreases baseline
repair, which is consistent with other
reports of the inverse-agonist activity of
ASIP for the MC1R ((Hida et al., 2009)
and Figure 1).
The third assay is a method to
quantify the ATR-pS435-dependent
recruitment of XPA to photodamaged
DNA in nuclear extracts. Nuclear
lysates of treated melanocytes (contain-
ing unknown levels of ATR-pS435 and
XPA) are incubated with the same
biotinylated UV-damaged oligonucleo-
tides described above. Once the
ATR-pS435 and XPA in the lysates have
bound to the UV-damaged oligonucleo-
tides, the oligos are retrieved using
streptavidin-coated beads, and bound
ATR-pS435 and XPA are quantiﬁed by
western blot. Using this assay the
authors found low baseline levels of
XPA and ATR-pS435 in unstimulated
cells, and 3–4-fold increases following
pre-incubation with α-MSH or forskolin.
Using these three assays, researchers
in the ﬁeld will now be able to system-
atically evaluate MC1R-dependent
repair of UV-damaged DNA, as
measured by the quantity of (1) ATR-
pS435, (2) repair of UV-damaged
oligonucleotides, and (3) XPA and
ATR-pS435 recruited to damaged
DNA. This tool-kit paves the way for
testing other candidate prevention
agents with the capacity to enhance
impaired MC1R functions. Agents that
could be evaluated using these methods
include α-MSH analogs (Abdel-Malek
et al., 2009), thymidine dinucleotides
(pTpT) designed as mimics of
UV-induced DNA damage (Goukassian
et al., 2012), and other pharmaco-
logic agents that might increase
levels of cAMP in the epidermis
(D’Orazio 2006).
Several investigative groups have
reported (Beaumont et al., 2007;
Kadekaro et al., 2010) that different
combinations of MC1R mutations result
in varying degrees of impairment of
cAMP generation in α-MSH-treated
melanocytes. The new assays reported
here will allow the examination in ﬁner
detail, of the molecular responses to
α-MSH in melanocytes with homo or
heterozygous loss-of-function mutations
in MC1R. These new methodologies
will also facilitate the investigation of
molecular underpinnings of the intri-
guing new ﬁndings from meta-analyses
of MC1R epidemiological studies that
suggest that melanoma risk is highest in
MC1R mutation carriers with darker
skin (Type III or higher), and without
red hair or freckles (Pasquali et al.,
2015). Determining whether these
phenomena are caused by altered
MC1R function, interactions between
mutated and wild-type MC1Rs, or,
alternatively, by some behavioral phe-
nomenon (e.g., less-effective sun-pro-
tective behaviors in individuals who do
not sunburn easily), will be vital to both
treatment and risk assessment of
patients with MC1R mutations who do
not have the canonical red-hair pheno-
type. These patients may merely need to
be reminded that a tan is not healthy for
them and they need to wear a hat, or
that they might beneﬁt speciﬁcally from
a pharmacological agent designed to
address the deﬁciency in NER in their
melanocytes. The studies and assays
discussed here will help in the design
optimal protocols for melanoma pre-
vention in these patients.
Questions and future directions
As with all important advances in
science, this report raises as many new
issues and questions as it answers. First,
these assays will need to be adapted for
use in human tissue samples to realize
their full potential. It is still uncertain
whether the effects described in these
cell-based systems will prove to be
relevant in vivo. If it is true that one of
the major underlying causes of
increased risk for melanoma in MC1R
mutation carriers is diminished NER
secondary to decreased ATR-pS435,
then how and why has this variation
been preserved evolutionarily? Does the
increase in vitamin D synthesis in fair
skinned individuals trump the skin
cancer risk because skin cancer occurs
later in life, after reproduction has been
accomplished? Is it possible that in vivo
there are redundant mechanisms in
place that can overcome the loss-of-
function of MC1R, perhaps by altering
the activities of α-MSH, ACTH, HBD3,
or ASIP? Is it possible that because of
the role of HBD3 in innate immunity
and inﬂammation in the skin, that
inﬂammatory conditions (e.g., sun-
burns, chronic wounds) or infection
could increase HBD3 levels and simul-
taneously reduce NER in melanocytes?
And ﬁnally, it is intriguing that repair of
Clinical Implications
● Discovery of the molecular mechanisms of DNA-damage repair down-
stream of MC1R will enable the design of targeted prevention agents and
risk assessment for melanoma.
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UV-induced DNA damage in melano-
cytes is regulated hormonally. What
biological advantage is conferred by
maintaining intermediate levels of
repair that can be upregulated and
downregulated by hormonal factors
produced locally and centrally? Is it
possible that DNA repair is playing a
role in the balance between cell
survival, senescence, and immortaliza-
tion of cancerous melanocytes? Could
reduction of repair mechanisms through
antagonism of MC1R function make
melanocytes or melanoma cells more
vulnerable to immunologic attack (e.g.,
in vitiligo or immunotherapy for mela-
noma) or sensitize these cells to
traditional DNA damaging chemother-
apeutics? These questions and ideas are
certainly not the only ones that could be
raised, but they will hopefully increase
readers’ appreciation of the clinical
relevance of this work as well as the
implications that extend from the ﬁelds
of pigmentation and melanoma to
inﬂammation, immunology, and, even,
infectious disease.
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Melanocyte Regeneration in Vitiligo
Requires WNT beneath their Wings
John E. Harris1
Melanocytes in patients with vitiligo possess intrinsic abnormalities that
contribute to its pathogenesis. Regazzetti et al. report that CXCL10 expression
reﬂects subtle inﬂammation in normal-appearing skin but not in stable
depigmented lesions, supporting the hypothesis that melanocytes themselves
initiate autoimmune inﬂammation prior to clinically evident disease. In addition,
they ﬁnd that oxidative stress in melanocytes impairs WNT signaling and that
targeting this pathway induces melanoblast differentiation. Thus, activating the
WNT pathway may serve as an adjunctive strategy to support repigmentation in
patients with vitiligo.
Journal of Investigative Dermatology (2015) 135, 2921–2923. doi:10.1038/jid.2015.372
Regazzetti et al. (2015) report that WNT
signaling is impaired in lesional and
nonlesional skin of patients with vitiligo.
Because WNT signaling promotes the
differentiation of melanocyte precursors
in skin (Yamada et al., 2013), impaired
signaling may affect the ability of
melanocytes to proliferate and differ-
entiate into functional melanocytes
during therapeutic repigmentation.
Current treatments for vitiligo include
topical anti-inﬂammatory compounds,
such as corticosteroids and calcineurin
inhibitors, which inhibit autoimmune
responses, as well as narrow-band ultra-
violet radiation B (nbUVB) (Ezzedine
et al., 2015), which likely inhibits auto-
immunity and promotes melanocyte
regeneration. Repigmentation in vitiligo
begins within 6–12 weeks after initiating
treatment, and it frequently occurs in a
perifollicular pattern (Figure 1). A recent
study has reported that nbUVB treatment
of vitiligo is associated with proliferation,
migration, and differentiation of melano-
cytes in the hair follicles and epidermis
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